terrein: from culture solution of fungus, Pestilotiopsis microspora;structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6436830 |
| CHEMBL ID | 506722 |
| CHEBI ID | 177543 |
| SCHEMBL ID | 1884980 |
| MeSH ID | M0404694 |
| Synonym |
|---|
| CHEBI:177543 |
| (4s,5r)-4,5-dihydroxy-3-[(e)-prop-1-enyl]cyclopent-2-en-1-one |
| terrein |
| NCGC00179945-01 |
| nsc-291308 |
| 582-46-7 |
| MEGXM0_000160 |
| ACON1_001984 |
| BRD-K68034638-001-01-1 |
| mhoopnkrbmhhec-hzibqtdnsa- |
| inchi=1/c8h10o3/c1-2-3-5-4-6(9)8(11)7(5)10/h2-4,7-8,10-11h,1h3/b3-2+/t7-,8-/m0/s1 |
| SCHEMBL1884980 |
| 2-cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)-, (4s-(3(e),4alpha,5beta))- |
| nsc 291308 |
| unii-3i47hpe16n |
| 3i47hpe16n , |
| 2-cyclopenten-1-one, 4,5-dihydroxy-3-propenyl- |
| AKOS006327725 |
| terrein [inci] |
| (+)-terrein |
| 2-cyclopenten-1-one, 4,5-dihydroxy-3-(1e)-1-propenyl-, (4s,5r)- |
| 2-cyclopenten-1-one, 4,5-dihydroxy-3-(1-propenyl)-, (4s-(3(e),4.alpha.,5.beta.))- |
| 2-cyclopenten-1-one, 4,5-dihydroxy-3-(1e)-1-propen-1-yl-, (4s,5r)- |
| CHEMBL506722 |
| (4s,5r)-4,5-dihydroxy-3-(1e)-1-propen-1-yl-2-cyclopenten-1-one |
| mfcd09752761 |
| (4s,5r)-4,5-dihydroxy-3-((e)-prop-1-en-1-yl)cyclopent-2-enone |
| HY-119808 |
| DTXSID101017469 |
| CS-0078056 |
| Q27257243 |
| terrain |
| (+)terrein |
Terrein is a small-molecule polyketide compound with a simple structure mainly isolated from fungi. It is a fungal metabolite with application values in the fields of medicine, cosmetology, and agriculture.
| Excerpt | Reference | Relevance |
|---|---|---|
| "(+)-Terrein has a potential application for drug discovery. " | ( Improving the yield of (+)-terrein from the salt-tolerant Aspergillus terreus PT06-2. Guo, L; Wang, L; Zhao, C; Zhu, G; Zhu, W, 2016) | 1.29 |
| "(+)-Terrein has a potential application for drug discovery. " | ( Improving the yield of (+)-terrein from the salt-tolerant Aspergillus terreus PT06-2. Guo, L; Wang, L; Zhao, C; Zhu, G; Zhu, W, 2016) | 1.29 |
Treatment with terrein at a concentration of 50 mum strongly decreased melanogenesis in a time-dependent manner. Treatment with Terrein suppressed growth of ABCG2-expressing breast cancer cells.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with terrein at a concentration of 50 mum strongly decreased melanogenesis in a time-dependent manner." | ( Long-term suppression of tyrosinase by terrein via tyrosinase degradation and its decreased expression. Kim, DS; Kim, WG; Kwon, SB; Lee, HK; Lee, S; Park, KC; Park, SH; Ryoo, IJ; Yoo, ID, 2009) | 0.96 |
| "Treatment with terrein (2) significantly suppressed growth of ABCG2-expressing breast cancer cells." | ( Asperjinone, a nor-neolignan, and terrein, a suppressor of ABCG2-expressing breast cancer cells, from thermophilic Aspergillus terreus. Chen, JW; Han, HY; Kuo, SC; Liao, WY; Liaw, CC; Lin, LH; Shen, CN; Wu, SH; Yang, YL, 2012) | 1 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The data suggest that KI-063 has an additive effect in combination with terrein." | ( The hypopigmentary action of KI-063 (a new tyrosinase inhibitor) combined with terrein. Baek, KJ; Kim, DS; Kwon, SB; Lee, HK; Lee, S; Na, JI; Park, KC; Park, SH; Ryoo, IJ; Yoo, ID, 2008) | 0.81 |
| Class | Description |
|---|---|
| polyol | A compound that contains two or more hydroxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1161130 | Inhibition of endogenous VEGF secretion in HGF cells at 0.01 to 10 uM by ELISA method | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| AID1161124 | Cytotoxicity against HGF cells assessed as cell proliferation at <10 uM incubated for 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| AID1161125 | Cytotoxicity against HGF cells assessed as reduction in cell proliferation at >50 uM incubated for 24 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| AID1161129 | Inhibition of IL-6/soluble IL-6 receptor signaling-induced JNK1/2 phosphorylation in HGF cells pre-incubated at 10 to 20 uM for before IL-6/soluble IL-6 receptor stimulation for 5 mins by Western blotting method | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| AID1161128 | Inhibition of IL-6/soluble IL-6 receptor signaling-induced ERK1/2 phosphorylation in HGF cells pre-incubated at 10 to 20 uM for before IL-6/soluble IL-6 receptor stimulation for 5 mins by Western blotting method | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| AID1161126 | Inhibition of IL-6/soluble IL-6 receptor signaling-induced VEGF secretion in HGF cells pre-incubated for 30 mins before IL-6/soluble IL-6 receptor stimulation for 24 hrs by ELISA method | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| AID1161127 | Inhibition of IL-6/soluble IL-6 receptor signaling-induced STAT3 phosphorylation in HGF cells pre-incubated at 10 to 20 uM for before IL-6/soluble IL-6 receptor stimulation for 5 mins by Western blotting method | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Synthetic (+)-terrein suppresses interleukin-6/soluble interleukin-6 receptor induced-secretion of vascular endothelial growth factor in human gingival fibroblasts. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (29.27) | 29.6817 |
| 2010's | 19 (46.34) | 24.3611 |
| 2020's | 10 (24.39) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (56.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (2.38%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 41 (97.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||